@entity1534 eradication therapy improves atrophic gastritis and intestinal metaplasia: a 5-year prospective study of XXXX with atrophic gastritis.

@entity1 @entity6693 @entity194 @entity3621 @entity1534 @entity8243 @entity356
AIM: : To investigate the effect of the eradication of @entity1534 on histological @entity3621 . METHODS: : Twenty-six @entity1 with moderate to severe @entity194 received successful eradication therapy of @entity1534 . Four @entity1 dropped out and 22 were followed up prospectively for 5 years. The grades of @entity3621 were estimated from gastric biopsy specimens. The grade of intestinal metaplasia was also evaluated by dye-endoscopy using @entity6693 ( @entity6693 ). The serum levels of pepsinogen, @entity8243 and anti-parietal cell antibody were also determined. RESULTS: : The grades of @entity194 decreased in @entity1 with successful eradication therapy in the gastric corpus (before vs. 5 years after eradication, 2.09 +/- 0.15 vs. 0.91 +/- 0.17; P < 0.01) and in the antrum (2.14 +/- 0.17 vs. 1.36 +/- 0.17; P < 0.01). The levels of intestinal metaplasia were also decreased in the corpus (0.91 +/- 0.24 vs. 0.50 +/- 0.16; P < 0.05) and in the antrum (1.41 +/- 0.20 vs. 1.00 +/- 0.16; P < 0.05), which was also demonstrated by the @entity6693 ( @entity6693 ) staining method (33.4 +/- 8.2% vs. 23.0 +/- 6.5%; P < 0.05). The improvement of @entity194 correlated well with the high serum level of pepsinogen I (P = 0.005), but showed no correlation with the levels of anti-parietal cell antibody. CONCLUSIONS: : These results suggest that @entity356 and intestinal metaplasia are reversible events in some @entity1 .
